EV-103: Enfortumab vedotin plus pembrolizumab shows sustained survival and durable responses after five years of follow-up in advanced urothelial carcinoma

CHICAGO 2026

Genitourinary Cancer

EV-302: The 3.5-year update shows that enfortumab vedotin plus pembrolizumab maintains durable survival benefit over chemotherapy in advanced urothelial carcinoma

ASH 2025

Lymphoma

TRANSCEND FL: High rates of deep and durable responses and sustained survival with liso-cel in patients with R/R FL after three years of follow-up

Genitourinary Cancer

Enfortumab vedotin plus pembrolizumab in treatment-naïve metastatic urothelial carcinoma patients: An Austrian real-world analysis

Int J Cancer

Niedersuess-Beke D, Mayrhofer K, Krauter J, Franke J, Vais D, Pallauf M, Kiesl D, Luger F, Pfuner J, Terbuch A, Bauernhofer T, Spielgelberg J, Banner A, Aufderklamm S, Wiesinger C, Schnabel S, Gampenrieder SP, Mühlmann J, Vallet S, Weibrecht S, Stoiber F, Andalibi H, Fajkovic H, Taghizadeh H, Miechowiecki J, Taedcke R, Heintel D, Shariat SF, Pichler M, Hilbe W, Pichler R

doi: 10.1002/ijc.70203

CHICAGO 2026

Breast Cancer

KEYNOTE-522: Pembrolizumab plus chemotherapy provides sustained EFS and OS benefits at 8-year follow-up in high-risk early-stage TNBC

ESMO 2026

Genitourinary Cancer

KEYNOTE-905: Perioperative enfortumab vedotin plus pembrolizumab improves outcomes in cisplatin-ineligible patients with muscle-invasive bladder cancer

Gastrointestinal Cancer

Nivolumab plus chemotherapy or ipilimumab versus chemotherapy as first-line treatment for advanced esophageal squamous cell carcinoma: 5-year follow-up results from CheckMate 648

Ann Oncol

Kato K, Ajani J, Doki Y, Xu J, Wyrwicz L, Motoyama S, Ogata T, Kawakami H, Hsu CH, Adenis A, Hajbi FE, Di Bartolomeo M, Braghiroli MI, Holtved E, Makino T, Murphy MB, Zhang J, Sharma P, He B, Lei M, Matsumura Y, Kitagawa Y, Chau I

doi: 10.1016/j.annonc.2026.08.001

Lung, Respiratory and Thoracic Cancer

Long-term survival with PD-1/PD-L1 inhibitors plus platinum-based chemotherapy versus chemotherapy alone in locally advanced or metastatic pulmonary lymphoepithelioma-like carcinoma: updated follow-up analysis

Lung Cancer

Tang Y, Du W, Zhang X, Yang X, Zhou Y, Fu S, Zhang L, Hong S

doi: 10.1016/j.lungcan.2025.108855

EHA 2026

Lymphoma

Mosunetuzumab plus lenalidomide induction with or without mosunetuzumab maintenance shows high and durable responses in patients with previously untreated FL

CHICAGO 2026

Genitourinary Cancer

Related content

EV-302: The 3.5-year update shows that enfortumab vedotin plus pembrolizumab maintains durable survival benefit over chemotherapy in advanced urothelial carcinoma

TRANSCEND FL: High rates of deep and durable responses and sustained survival with liso-cel in patients with R/R FL after three years of follow-up

Enfortumab vedotin plus pembrolizumab in treatment-naïve metastatic urothelial carcinoma patients: An Austrian real-world analysis

KEYNOTE-522: Pembrolizumab plus chemotherapy provides sustained EFS and OS benefits at 8-year follow-up in high-risk early-stage TNBC

KEYNOTE-905: Perioperative enfortumab vedotin plus pembrolizumab improves outcomes in cisplatin-ineligible patients with muscle-invasive bladder cancer

Nivolumab plus chemotherapy or ipilimumab versus chemotherapy as first-line treatment for advanced esophageal squamous cell carcinoma: 5-year follow-up results from CheckMate 648

Long-term survival with PD-1/PD-L1 inhibitors plus platinum-based chemotherapy versus chemotherapy alone in locally advanced or metastatic pulmonary lymphoepithelioma-like carcinoma: updated follow-up analysis

Mosunetuzumab plus lenalidomide induction with or without mosunetuzumab maintenance shows high and durable responses in patients with previously untreated FL

ENGOT-EN6-NSGO/GOG-3031/RUBY: Post hoc analyses show sustained survival benefit with dostarlimab plus chemotherapy in dMMR/MSI-H endometrial cancer